A prospective multicenter trial, LOCATE, assessing the impact of 18F-fluciclovine PET/CT imaging in patients with biochemical recurrence of prostate cancer (median PSA 1.0 ng/mL) after primary therapy with curative intent, demonstrated 18F-fluciclovine avid lesions in 122 of the 213 patients (57%) [53]. The gene discussed is KLK3; the disease is prostate cancer.